RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31
RBC Capital Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Analyst Ratings
Express News | NewAmsterdam Pharma Company NV : Leerink Partners Raises Target Price to $45 From $42
Buy Rating for NewAmsterdam Pharma Amid Promising TANDEM Trial Results and Upcoming BROADWAY Trial Expectations
NewAmsterdam Pharma Down Over 15%, On Track for Largest Percent Decrease Since June 2023 -- Data Talk